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ORAL CANCER
ies were listed as follows: systematic and non-systematic reviews; microbiology studies; growth and development studies; organ transplant studies; studies eliciting dental complications through questionnaires; studies reporting data from previous publications; phase I and II studies, opinion papers and case reports; articles published before 1990.
Of the 64 studies included, 46 were observational and 18 interventional. In regards to the age of the population sampled, 31 studies recruited adults, 24 recruited children, four included both paediatric and adult patients and age was not stated in five studies. The two most common malignancies in the review were head and neck cancer and haematological malignancies. Concerning the treatment modality listed in the 64 studies, 22 studies (n=710 pts) included chemotherapy only; 30 studies included radiation only (n=3477pts);
19 studies included radiation and chemotherapy (n=696 pts), whereas in seven studies (n=1812 pts) there was no breakdown or a vague description of administered cancer therapy.
Prevalence of dental and periodontal disease in cancer survivors
Of the 46 observational studies that were included to evaluate the weighted prevalence of dental disease, 24 were cohort, eight case control and 14 cross-sectional studies.
The overall weighted prevalence of dental caries was 28.1% and was determined from 19 studies. Unexpectedly, the weighted prevalence of dental caries in patients who only received chemotherapy seemed to be highest (37.3%, 95%CI 0-85.7) when compared to those who received radiotherapy (24.1%, 95%CI 0-66. 2) or to patients receiving chemoradiotherapy (21.4%, 95%CI 6.9-35.8). Authors considered two reasons for this unanticipated caries prevalence. The first explanation is that patients undergoing head and neck radiotherapy are at lifelong risk of developing osteoradionecrosis, thus dental management protocols in these patients may require more aggressive approaches (ie dental extractions) than those being prepared for chemotherapy. The other reason explained by the authors is that the majority of the studies (12 of the 19 studies) were conducted in paediatric populations with a high proportion of haematologic malignancies requiring high doses of chemotherapy, and who frequently take sugar-rich medications or consume cariogenic dietary supplements. The overall DMFT for patients who were post-cancer therapy was 9.19(SD 7.98; n=457). When DMFT was estimated by treatment groups, patients who were post-radiotherapy presented higher index values than those who received chemotherapy, DMFT 17.01 (SD 9.14; n=157) and 4.5 (SD 2.88; n=132), respectively.
In regards to periodontal disease in cancer patients, results
showed that the weighted prevalence of severe gingivitis from three cohort studies was 20.3% (SE 0.49, 95%CI 0-41.4). The Gingival Index (GI) for patients who were post-chemotherapy was 1.02(SD 0.15; n=162). The overall Plaque Index (PI) for patients who were post-antineoplastic therapy was 1.38 (SD 0.25; n=189) and the PI for patients who were post-chemotherapy was 1.46 (SD 0.23; n=162)
Systemic infections from oral sources
Febrile episodes associated with odontogenic infections have been reported in two studies that were conducted on patients undergoing intensive chemotherapy regimens. In one of the studies, the reported incidence of febrile episode originating from a dental problem was 4%, (n=48) and this finding represented a relative incidence rate of 10% for acute conversion of previously diagnosed severe chronic dental disease. 6 In the second study, no source of infection other than an oral one was found in 42% of the recorded febrile episodes. 7 This study also reported that patients with febrile episodes had more severe dental infection (57.6%) than those without (23.3%).
Strengths and weaknesses of this systematic review
While evidence of toxicity on oral mucosal lining and on salivary glands as direct consequences in chemotherapy and/or radiotherapy of head and neck cancer has been shown in well-designed studies, [8] [9] [10] identification, appraisal and synthesis of the literature on dental and periodontal complication in cancer patients had not been accomplished since 1989. Due to the significant advances in cancer therapies in the past decades (ie intensity of chemotherapy regimens, intensity modulated radiation therapy, use of radioprotective agents, etc) it is expected that new evidence on trends in prevalence, nature and severity of these oral complications has been accrued. Thus, the relevance and usefulness of this review is imperative for dental clinicians in treating these patients.
As for the review methodology, this review had a number of limitations. A key source of potential bias in a systematic review is bias due to limitations in the original studies contained within it. Regarding study selection for this review, no inclusion criteria were stated. Authors mentioned having considered scientific quality methods of assessment to determine the weighted prevalence of caries and dental infection. However, quality assessment is not clearly documented in the article. In addition, the search was restricted to English language publications and given the worldwide oral complications in cancer patients, this restriction may have introduced bias.
In relation to the clinical question about prevalence of caries and of periodontal disease, observational studies were included in the review. Almost half of them being were case control and cross sectional studies (22 of the 46). Despite the methodological quality of included studies, the authors did not mention how they treated possible bias inherent to study designs (loss to follow up, selection bias and misclassification) or potential confounding variables.
Although treatment modality is one of the most relevant variables to be considered in prevalence calculation for cancer survivors, it is worth noting that in seven studies included (n=1812 pts) there was no breakdown or a vague description of administered cancer therapy. In spite of the intuitive appeal of overall weighted prevalence, its dependence on prevalence from studies where the study population diverges considerably may particularly mislead the real prevalence in the cancer population setting. [10] [11] [12] Unfortunately, a comprehensive list of included studies to calculate prevalence was not provided in this review. It is important to remark that although the authors reported weighted prevalence as the main outcome, methods to address and calculate weighting were not stated in the article. Moreover, it was not clear what is the total number of patients who were included for prevalence calculation. Besides clinical differences between the groups mentioned by the authors when obtaining the overall weighted prevalence of caries, the wide range of its 95% CI in the three groups may suggest a small sample size in each group, or other clinical differences such as age, dif-ferent chemotherapeutic drugs or other medications, etc between the groups of patients included from different studies. Therefore, it is suggested that any conclusion about these findings should be drawn with caution.
Concerning the prevalence of severe gingivitis, although it was obtained only in patients undergoing chemotherapy for acute leukaemia treatment, two of them included a paediatric population, 13, 14 and only one study included adult patients. Within the study which included adults, 50% of patients received plaque control using 0.1% chlorhexidine solution and in the other 50% of patients this measure was preceded by mechanical removal of plaque and calculus on day one. 15 This may suggest that the study population used to obtain gingivitis severity could not have been at the same baseline risk. It is worth noting that the three studies included to obtain Gingival Index were conducted to evaluate long-term effects of chemotherapy in paediatric groups. [16] [17] [18] [19] Considering the potential aggressiveness of severe gingivitis in patients who undergo high dose chemotherapy, these GI values may not be representative for this patient cancer group. The authors pointed out that attempts to describe periodontal health and periodontal disease beyond PI and GI indices in cancer patients were difficult in this review. Reasons stated were: the variety of outcome variables reported; the ambiguity in the categorisation and definition of periodontal status; and the scarcity of more representative measurements of periodontal status reported in the articles.
The authors concluded that patients who were post-radiotherapy had the highest DMFT compared to those who were post-chemotherapy and healthy controls. Even though no statistical test to analyse this difference between groups was mentioned, clinical differences between groups can explain this result. While radiation damage is anatomically site-specific, chemotherapy often can cause both site-specific and non-oral toxicity. Consequently, it is expected to see differences in the prevalence of caries and periodontal disease among these two distinct groups of patients. Because of direct radiation toxicity on the dental apparatus and because of the xerostomia resulting from degenerative radio effects on salivary gland parenchyma, a higher prevalence of caries is to be expected in patients who undergo radiotherapy. As the result of myelosupression and loss of protective salivary constituents, patients who undergo high dose chemotherapy regimens are expected to have a higher prevalence of periodontal disease. Therefore, prevalence or incidence studies disaggregated by these distinct groups of patients would be required to assess the real overall prevalence of dental and periodontal disease.
Despite the reported low prevalence of systemic infection associated with a periodontogenic or odontogenic source, there is evidence that these infections may become potentially life-threatening in myelosuppressed cancer patients. Based on this theoretical reasoning and indirect evidence, it seems reasonable to suggest that all acute and potential sources of oral infections should be correctly eradicated. Due to the distinct consequences of the presence of dental infection between patients who undergo intensive chemotherapy versus patients undergoing radiotherapy, the results of this evidence cannot be extrapolated to patients who receive ionising radiation for cancer treatment. Obviously, large prospective studies would be required to definitively address proper pre-cancer therapy clearance protocols in this patient setting.
In conclusion, this review emphasises the current scarcity of well-designed studies to evaluate the extent and severity of dental and periodontal diseases associated with complications during cancer therapy. The authors underscored the lack of specification and standardisation, and wide ranges of time periods of index values data collection.
Implications for Dental Practitioners
Oral complications from radiation to the head and neck or chemotherapy for any malignancy can compromise patients' health and affect their ability to complete planned cancer treatment. On occasions, the complications can be so debilitating that they may postpone scheduled treatments, or discontinue treatment entirely. Oral complications can also lead to serious systemic infections. Medically necessary oral care before, during and after cancer treatment can prevent or reduce the incidence and severity of oral complications, enhancing both patient survival and quality of life. 
